Eli Lilly leads in GLP-1 weight loss drugs, sparking investor interest in stock price. Concerns arise due to heavy reliance on GLP-1 drugs for revenue. Novo Nordisk, the first to market GLP-1 drugs, now trails Eli Lilly. Stock has soared 164% in 3 years, but risks include patent expiration and competition.

Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound are blockbusters, driving stock success. However, reliance on these drugs for revenue poses a risk. Novo Nordisk was displaced by Eli Lilly, but competition remains fierce in the pharmaceutical sector. Investors must weigh the potential for future success against patent expirations and market competition.

Read more at Yahoo Finance: This Skyrocketing Stock Has a Hidden Risk